Compare Equinor ASA (EQNR) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinor ASA vs Sana Biotechnology Inc — how do they compare? Equinor ASA trades at $40.95 (market cap $97.58B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Equinor ASA is far larger — about 86.4× Sana Biotechnology Inc's market cap, and Equinor ASA pays a 3.81% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| EQNR | SANA | |
|---|---|---|
Market Cap | $97.58B | $1.13B |
Sector | Energy | Health |
52-Week High | $42.40 | $5.92 |
52-Week Low | $22.41 | $2.68 |
Enterprise Value | $106.28B | $1.05B |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinor (EQNR) trades at $40.92, down slightly by 0.17% on the day, with strong technical momentum showing a bullish moving average signal. The company delivered mixed Q2 2026 earnings with a revenue beat but EPS miss, while maintaining robust cash flow generation and shareholder returns through dividends and buybacks. Recent news highlights strong quarterly performance driven by higher energy prices and production growth.
EQNR presents a compelling value case with attractive valuation multiples (P/E 11.09, EV/EBITDA 2.3) and solid profitability metrics (ROE 21.32%). However, declining profit margins from 19.29% in 2022 to 4.76% in 2025 and analyst caution (56.53% hold rating) suggest balanced risk-reward. The stock offers income potential with consistent dividends amid energy market volatility.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
